Investor Presentation for the quarter ended 30 June 2026.
Investor Presentation - Q1FY27
- Revenue from operations 1.67bn INR, +43% y-y; EBITDA 323mn INR, margin 19%, +430 bps y-y; PAT 160mn INR, margin 10%, +400 bps y-y
- FY26 revenue grew 32% to 5.06bn INR; EBITDA margin improved to 18%, PAT margin 8%
- Product mix: SDA 34%, PASC 35%, PTC 26%, ESS 4% in Q1FY27
- Focus on green chemistry with electrolysis and continuous flow chemistry for sustainable growth
- Expanding global presence with exports to 25+ countries and subsidiaries in USA and Netherlands
- Strong R&D with 56 employees and advanced labs supporting innovation
- Industry outlook positive with India gaining market share due to China+1 policy and green chemistry trends
Source: Original filing PDF
—
view on exchange portal
⚡ You're reading this after the fact — subscribers got it instantly
ISA
Indian Stock Alerts
BOT
🚨 TATVA — Quarterly Results
Revenue: ₹2,35,800 Cr (+12% YoY)
PAT: ₹19,200 Cr (+17% YoY)
EBITDA margin: 16.8%
Board declared ₹10/share dividend. Jio adds 8M subs.
📎 bseindia.com/xml-data/...
🎧 Audio summary ready
✓✓ 6:47 PM
Instant audio summaries2-min AI concall recap delivered with every earnings alert
20-quarter financialsRevenue, PAT, EBITDA, margins — auto-extracted from filings
Forensic red-flag screenAudit, governance, accruals & RPT flags scored automatically
Instant Telegram alertsResults, board meetings, insider trades — within minutes
Add TATVA to your watchlist — all of this, automated.
Sign in with Google14-day Pro trial · No credit card · Cancel anytime
More on Tatva Chintan Pharma Chem Limited
Important.
The summary above is generated automatically from Tatva Chintan Pharma Chem Limited's own
public regulatory filing under SEBI LODR. Indian Stock Alerts is
not a SEBI-registered Research Analyst or Investment Adviser.
This page is informational, not investment advice, a recommendation to buy
or sell any security, or any opinion about the company's business, governance
or financial health. Always read the original filing before acting and consult
a registered adviser for investment decisions.